http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
TC1 (C8orf4) is involved in ERK1/2 pathway-regulated G1-to S-phase transition
( Yi Dong Wang ),( Guo Hui Bian ),( Xiao Yan Lv ),( Rong Zheng ),( Huan Sun ),( Zheng Zhang ),( Ye Chen ),( Qin Wei Li ),( Yan Xiao ),( Qiu Tan Yang ),( Jian Zhong Ai ),( Yu Quan Wei ),( Qin Zhou ) 생화학분자생물학회 2008 BMB Reports Vol.41 No.10
Jiang, Ping,Yu, Guo-Yu,Zhang, Yong,Xiang, Yang,Hua, Hai-Rong,Bian, Li,Wang, Chun-Yan,Lee, Wen-Hui,Zhang, Yun Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.6
The role of protease-activated receptors (PARs) in lung tumors is controversial. Although PAR4 is preferentially expressed in human lung tissues, its possible significance in lung cancer has not been defined. The studies reported herein used a combination of clinical observations and molecular methods. Surgically resected lung adenocarcinomas and associated adjacent normal lung tissues were collected and BEAS-2B and NCI-H157 cell lines were grown in tissue culture. PAR4 expression was evaluated by RT-PCR, RT-qPCR, Western blotting and immunohistochemistry analysis. The results showed that PAR4 mRNA expression was generally decreased in lung adenocarcinoma tissues as compared with matched noncancerous tissues (67.7%) and was associated with poor differentiation (p=0.017) and metastasis (p=0.04). Western blotting and immunohistochemical analysis also showed that PAR4 protein levels were mostly decreased in lung adenocarcinoma tissues (61.3%), and were also associated with poor differentiation (p=0.035) and clinical stage (p=0.027). Moreover, PAR4 expression was decreased in NCI-H157 cells as compared with BEAS-2B cells. In conclusion, PAR4 expression is significantly decreased in lung adenocarcinoma, and down-regulation of PAR4 is associated with a more clinically aggressive phenotype. PAR4 may acts as a tumor suppressor in lung adenocarcinoma.